Short-term survivorship of antioxidant highly cross-linked polyethylene liners in total hip arthroplasty reported in American Joint Replacement Registry

Table 1 Subject demographics of Novation, Alteon, and aggregate antioxidant groups, n (%)

	Novation (n = 461)	Alteon (n = 989)	Aggregate antioxidant (n = 39964)	Novation vs aggregate, P value	Alteon vs aggregate, P value
Age - mean (SD)	72.55 (5.92)	74.01 (6.43)	72.92 (6.30)	0.21	< 0.0001
Follow-up (months) - mean (SD)	33.07 (8.59)	14.84 (8.20)	53.21 (24.01)	< 0.0001	< 0.0001
Sex				0.12	0.30
Female	291 (63.26)	572 (57.84)	23722 (59.54)	-	-
Male	169 (36.74)	417 (42.16)	16121 (40.46)	-	-
Unknown	1	0	121	-	-
Charlson index – mean (SD)	2.89 (0.91)	3.18 (1.16)	3.00 (1.09)	0.01	< 0.0001
Primary OA diagnosis				0.40	< 0.0001
Yes	439 (95.85)	838 (88.68)	37305 (94.88)	-	-
No	19 (4.15)	107 (11.32)	2014 (5.12)	-	-
Unknown	3	44	645	-	-

OA: Osteoarthritis.

Table 2 Revision rate and reason for revision rates for Novation, Alteon, and aggregate antioxidant groups, n (%)

Revisions	Novation (n = 461)	Alteon (n = 989)	Aggregate antioxidant (n = 39964)	Novation vs aggregate, P value	Alteon vs aggregate, P value
All-cause	4 (0.87)	18 (1.82)	986 (2.47)	0.02	0.23
Fracture (including periprosthetic fracture)	2 (0.43)	6 (0.61)	247 (0.62)	0.99	0.99
Infection	0 (0.00)	6 (0.61)	205 (0.51)	0.18	0.86
Aseptic loosening	0 (0.00)	2 (0.20)	116 (0.29)	0.65	0.99
Instability	0 (0.00)	3 (0.30)	248 (0.62)	0.12	0.30
Mechanical complications	0 (0.00)	2 (0.20)	101 (0.25)	0.63	0.33
Hematoma or wound complications	0 (0.00)	1 (0.10)	24 (0.06)	0.99	0.46
Wear	0 (0.00)	0 (0.00)	3 (0.01)	0.99	0.99
Pain	0 (0.00)	2 (0.20)	80 (0.20)	0.99	0.99
Revisions for all other reasons	2 (0.43)	1 (0.10)	229 (0.57)	0.19	0.05

F¹ “Other” reasons include non-specific or possibly irrelevant/erroneous diagnoses including cardiac conditions, hypertension, obesity, etc.

Table 3 Cumulative percent revision rates for Novation, Alteon, and aggregate antioxidant liner groups

	Novation (n = 461)	Alteon (n = 989)	Aggregate antioxidant (n = 39964)
Years to Revision	Cumulative Percent Revision% [95%CI] (Number at risk)
0	0.10% [0.00-0.19] (460)	0.25% [0.12-0.37] (989)	0.25% [0.20-0.30] (39843)
1	0.71% [0.01-1.40] (443)	1.79% [0.97-2.60] (584)	1.82% [1.69-1.95] (37561)
2	0.83% [0.02-1.64] (394)	2.09% [1.13-3.03] (162)	2.12% [1.98-2.27] (35337)
3	0.91% [0.02-1.79] (186)	2.27% [1.23-3.31] (2)	2.31% [2.16-2.46] (27951)

Table 4 Hazard ratios for statistical comparison of survivorship

Comparison	Hazard ratio	Confidence interval	P value
Novation vs aggregate antioxidant	0.389	0.146-1.04	0.060
Alteon vs aggregate antioxidant	0.982	0.615-1.567	0.940